- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
CNAT
3 Stocks to Watch on Tuesday: Biogen Inc (BIIB), Conatus Pharmaceuticals Inc (CNAT) and General Motors Company (GM)
Biogen (BIIB) announced a major management change, Conatus (CNAT) inked a liver drug deal with Novartis and GM (GM) slows sedan production.
52 Biotechnology Stocks to Sell Now
The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
3 Stocks to Watch on Tuesday: Salesforce.com, Inc. (CRM), TerraForm Power, Inc. (TERP) and Conatus Pharmaceuticals Inc (CNAT),
Salesforce.com (CRM) buys Krux, Conatus Pharmaceuticals (CNAT) surges on an encouraging update and TerraForm Power (TERP) gets a response from SunEdison.
32 Biotechnology Stocks to Sell Now
The ratings of 32 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
33 Biotechnology Stocks to Sell Now
This week, the ratings of 33 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
29 Biotechnology Stocks to Sell Now
This week, the overall grades of 29 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
28 Biotechnology Stocks to Sell Now
This week, the overall grades of 28 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
15 Biotechnology Stocks to Buy Now
The grades of 15 biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Biotech Stocks With Upside Target Ebola, Liver Disease
Developing successful Ebola and liver disease treatments is an incredibly risky opportunity for biotech stocks to create value.
